ViewPoint Therapeutics Competitors and Similar CompaniesClear all

ViewPoint Therapeutics's competitors and similar companies include Molecular Partners, Y-mAbs Therapeutics and Prevail Therapeutics.

	ViewPoint Therapeutics ViewPoint Therapeutics is a biotechnology company which develops treatments for diseases of protein misfolding, including cataracts.	Molecular Partners Molecular Partners is a company that develops biopharmaceutical products for serious diseases.	Y-mAbs Therapeutics Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets.	Prevail Therapeutics Prevail Therapeutics is a biotech company that is developing therapeutics for neurodegenerative disorders, such as Parkinson's disease.
Founding Date	Founding Date 2014	Founding Date 2004	Founding Date 2014	Founding Date 2017
Type	Type Private	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech clinical research drug development pharma therapy	Tags Healthcare biotech clinical research drug development pharma therapy	Tags Healthcare biotech clinical research drug development pharma therapy	Tags Healthcare biotech clinical research drug development pharma therapy
Locations	Locations San Mateo, US HQ San Francisco, US	Locations Zürich-Schlieren, CH HQ Cambridge, US Concord, US	Locations New York, US HQ Copenhagen, DK Nutley, US	Locations New York, US HQ
Employees	Employees 1	Employees 158	Employees 3239% increase	Employees 489% increase
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 657 m	Valuation ($) 787.7 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $87.7m (FY, 2024)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods $15m (FY, 2024)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit $72.7m (FY, 2024)	Gross profit N/A
Net income	Net income N/A	Net income (CHF61.7m) (FY, 2025)	Net income ($29.7m) (FY, 2024)	Net income ($63.2m) (FY, 2019)
Funding
Total funding raised	Total funding raised $ 39m	Total funding raised N/A	Total funding raised $ 80m	Total funding raised $ 125m